How Pharma Can Navigate Innovation and Cost Pressures in the GLP-1 Era
August 6th 2025In the second part of his Pharma Commerce video interview, Philip Sclafani, PwC's pharmaceutical and life sciences lead, discusses how the pharmaceutical industry is balancing high-cost innovation, especially in obesity and metabolic disease, with payer demands for cost containment, highlighting the growing role of biosimilars and future generics in offsetting spend.
Lessons From Shortages and Global Disruptions
August 5th 2025In the fifth part of her Pharma Commerce video interview, Heather Zenk, Cencora’s president of US supply chain, explores how public-private collaboration, smarter sourcing strategies, and long-term manufacturer support are helping to fortify pharmaceutical supply chains against future crises.
Pharma Industry Shifts Toward Full Activation
August 4th 2025In the fourth part of her Pharma Commerce video interview, Heather Zenk, Cencora’s president of US supply chain, explores how public-private collaboration, smarter sourcing strategies, and long-term manufacturer support are helping to fortify pharmaceutical supply chains against future crises.
The Twin Forces Shaping Pharma Logistics Sustainability
August 4th 2025In the final part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Nate Chenenko, principal with Ducker Carlisle, explains that as regulatory frameworks tighten across Europe and the United States, and customer preferences lean greener, pharma logistics leaders must balance compliance, cost, and innovation to meet mounting sustainability demands.
Peer Exchange: Leveraging Technology to Strengthen Pharma’s Fight Against Counterfeits (Episode 6)
August 1st 2025In the sixth part of this roundtable discussion, subject matter experts discuss how serialization, traceability tools, and multi-layered authentication technologies are becoming essential to proactive quality contingency planning, as counterfeiters grow more sophisticated.
FDA Delays Regeneron’s Odronextamab, Eylea HD Regulatory Decisions Over Catalent Site Issues
Regeneron has received a second complete response letter from the FDA for odronextamab and anticipates delays for Eylea HD due to inspection findings at a Catalent manufacturing site, despite continued strong revenue growth and pipeline momentum.
From Aisles to Access: How Grocery-Based Pharmacies are Evolving into Community Health Hubs
August 1st 2025Amid the growing crisis of pharmacy deserts, these entities are tapping new avenues in care delivery, including the integration of clinical services, nutrition counseling, and real-time patient education.
Balancing Compliance and Supply Chain Continuity
August 1st 2025In the third part of her Pharma Commerce video interview, Heather Zenk, Cencora’s president of US supply chain, explores how public-private collaboration, smarter sourcing strategies, and long-term manufacturer support are helping to fortify pharmaceutical supply chains against future crises.
Emission-Reduction Strategies That Save Money and Preserve Performance
July 31st 2025In the fourth part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Nate Chenenko, principal with Ducker Carlisle, shares best practices for reducing greenhouse gas emissions across distribution channels without disrupting supply chain efficiency.
Using Data Loggers and Cold Chain Tech to Power Precision Pharma Delivery
July 31st 2025In the second part of her Pharma Commerce video interview, Heather Zenk, Cencora’s president of US supply chain, explores how public-private collaboration, smarter sourcing strategies, and long-term manufacturer support are helping to fortify pharmaceutical supply chains against future crises.
Tackling ESG Data Gaps in Supplier and Third-Party Reporting
July 30th 2025In the third part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Nate Chenenko, principal with Ducker Carlisle details how manufacturers can overcome the data gaps from suppliers and third parties when aiming for sustainability certifications or ESG reporting compliance.
High Out-of-Pocket Costs Burden Privately Insured Cancer Patients, Study Finds
July 30th 2025A JAMA Network Open study reveals that patients with private insurance can face monthly costs nearing $600 after a cancer diagnosis, highlighting the disparities based on cancer stage and calling for stronger financial support policies.
How Predictive Maintenance and Localized Distribution Are Shaping Pharma’s Future
July 30th 2025In the first part of her Pharma Commerce video interview, Heather Zenk, Cencora’s president of US supply chain, explores how public-private collaboration, smarter sourcing strategies, and long-term manufacturer support are helping to fortify pharmaceutical supply chains against future crises.